Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma

Cancer Research

Volumn 72, Issue 6, 2012, Pages 1395-1406

  Corre, Jill ^a   Labat, Elodie ^a   Espagnolle, Nicolas ^a   Hébraud, Benjamin ^a   Avet Loiseau, Hervé ^a,c   Roussel, Murielle ^a   Huynh, Anne ^a   Gadelorge, Mélanie ^a   Cordelier, Pierre ^a   Klein, Bernard ^d   Moreau, Philippe ^a,c   Facon, Thierry ^a,e   Fournié, Jean Jacques ^a   Attal, Michel ^a   Bourin, Philippe ^a,b  

^a CHU PURPAN   (France)

^b CSA21   (France)

^c HÔTEL DIEU   (France)

^d INSERM   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; GROWTH DIFFERENTIATION FACTOR 15; LENALIDOMIDE; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PREDNISONE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GROWTH DIFFERENTIATION FACTOR 15 BLOOD LEVEL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STEM CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; STROMA CELL; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; BORONIC ACIDS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MALE; MELPHALAN; MESENCHYMAL STEM CELLS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; SIGNAL TRANSDUCTION; THALIDOMIDE;

EID: 84858175766     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0188     Document Type: Article

References (50)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009;374:324-39.
2. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502. (Pubitemid 38010075)
3. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
4. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-6.
5. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells 1995;13 Suppl 2:56-63.
6. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, et al. Plasmablastic morphology - an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998;91:2501-7. (Pubitemid 28155526)
7. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
8. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546-58. (Pubitemid 38235629)
9. Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005;23:6339-44. (Pubitemid 46218844)
10. Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol 2007;20:625-35. (Pubitemid 350225352)
11. Rajkumar SV, Buadi F. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. Best Pract Res Clin Haematol 2007;20:665-80. (Pubitemid 350215386)
12. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD Jr, Barlogie B, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009;113:4614-26.
13. Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC, Anderson KC. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 2007;101:950-68. (Pubitemid 47040875)
14. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23:10-24.
15. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712-20. (Pubitemid 24006055)
16. Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000;96:1953-60. (Pubitemid 30661083)
17. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15:1950-61. (Pubitemid 33115003)
18. Barille-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, et al. Advances in biology and therapy of multiple myeloma. Hematology Am Soc Hematol Educ Program 2003:248-78.
19. Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 2001;91:1219-30. (Pubitemid 32267031)
20. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne M, Crinquette A, et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007;21:158-63. (Pubitemid 44921847)
21. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007;21:1079-88. (Pubitemid 46672085)
22. Eling TE, Baek SJ, Shim M, Lee CH. NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol 2006;39:649-55. (Pubitemid 44892888)
23. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M,He XY, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997;94:11514-9. (Pubitemid 27451030)
24. Moore AG, Brown DA, Fairlie WD, Bauskin AR, Brown PK, Munier ML, et al. The transforming growth factor-β superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab 2000;85:4781-8. (Pubitemid 32157666)
25. Tong S, Marjono B, Brown DA, Mulvey S, Breit SN, Manuelpillai U, et al. Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. Lancet 2004;363:129-30. (Pubitemid 38068331)
26. Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, et al. GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res 2010;16:3851-9.
27. Brown DA, Lindmark F, Stattin P, Balter K, Adami H-O, Zheng SL, et al. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res 2009;15:6658-64.
28. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003;9:2642-50. (Pubitemid 36842108)
29. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006;12:442-6. (Pubitemid 43166133)
30. Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S, et al. Common cancer biomarkers. Cancer Res 2006;66:2953-61.
31. Kim KK, Lee JJ, Yang Y, You KH, Lee JH. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 2008;29:704-12. (Pubitemid 351494157)
32. Boyle GM, Pedley J, Martyn AC, Banducci KJ, Strutton GM, Brown DA, et al. Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol 2008;129:383-91.
33. Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, Russell PJ, et al. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003;63:5034-40. (Pubitemid 37022642)
34. Baek SJ, Okazaki R, Lee SH, Martinez J, Kim JS, Yamaguchi K, et al. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 2006;131:1553-60. (Pubitemid 44708948)
35. Harashima A, Matsuo Y, Nishizaki C, Kozuka T, Fukuda S, Sezaki T, et al. Human bone marrow stroma-dependant myeloma sister cell lines MOLP-6 and MOLP-7 derived from a patient with multiple myeloma. Human Cell 2000;13:43-54.
36. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-Kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000;60:6763-70.
37. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003;100:3410-5. (Pubitemid 36356597)
38. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M, et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 2006;66:4983-6. (Pubitemid 43852864)
39. Hsu J-h, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001;98:2853-5.
40. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001;20:5991-6000. (Pubitemid 32955041)
41. Zollinger A, Stuhmer T, Chatterjee M, Gattenlohner S, Haralambieva E, Muller-Hermelink H-K, et al. Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 2008;112:3403-11.
42. Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, Dorken B, et al. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004;18:1883-90. (Pubitemid 39530020)
43. Park YJ, Lee H, Lee JH. Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells. BMB Rep 2010;43:91-6.
44. Huang C-Y, Beer TM, Higano CS, True LD, Vessella R, Lange PH, et al. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res 2007;13:5825-33. (Pubitemid 47583907)
45. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009;114:3625-8.
46. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 2006;98:342-50.
47. de Jager SCA, Bermùdez B, Bot I, Koenen RR, Bot M, Kavelaars A, et al. Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. J Experimental Medicine 2011;208:217-25.
48. Staff AC, Trovik J, Zahl EAG, Wik E, Wollert KC,Kempf T, et al. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clinical Cancer Research 2011;17:4825-33.
49. Hsiao EC, Koniaris LG,Zimmers-Koniaris T, Sebald SM, Huynh TV, Lee SJ. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol 2000;20:3742-51. (Pubitemid 30243919)
50. Strelau J, Strzelczyk A, Rusu P, Bendner G, Wiese S, Diella F, et al. Progressive postnatal motoneuron loss in mice lacking GDF-15. J Neurosci 2009;29:13640-8.